AQST Aquestive Therapeutics Inc.

4.86
+0.05  (+1%)
Previous Close 4.81
Open 4.86
Price To Book -20.25
Market Cap 121,379,176
Shares 24,975,139
Volume 1,096
Short Ratio
Av. Daily Volume 116,756

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date November 30, 2019.
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
Rolling NDA filing has commenced - noted June 4, 2019. To be completed 4Q 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
CRL issued January 30, 2019 through partner Sunovion (private company).
APL-130277
Parkinson’s Disease with motor fluctuations
Phase 1 data due 3Q 2019.
AQST-108
Anaphylaxis

Latest News

  1. Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
  2. Aquestive Therapeutics Completes Enrollment in Libervant™ (diazepam buccal film) Crossover Study
  3. Aquestive Therapeutics: 1Q Earnings Snapshot
  4. IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
  5. Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
  6. Aquestive Therapeutics Announces Daniel Barber Named to Chief Operating Officer
  7. Need To Know: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Insiders Have Been Buying Shares
  8. Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019
  9. Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
  10. Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
  11. Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
  12. Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  13. Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
  14. Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019
  15. Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
  16. Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation
  17. Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
  18. Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen